Investor Day Reduced-Risk Products Lausanne, September 29, 2016
|
|
- Valentine Flowers
- 6 years ago
- Views:
Transcription
1 Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products Mirek Zielinski President, Reduced-Risk Products
2 Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products 2
3 Agenda Reduced-Risk Products (RRPs) Scientific Substantiation Progress RRP Regulation RRP Portfolio and Commercialization Approach 3
4 Disease Risk Cessation: The "Gold Standard" We apply the U.S. Institute of Medicine s "gold standard" for assessing risk reduction: benchmark against cessation From Epidemiology Point of Intervention Time. The descriptions in the chart are for illustrative purposes only Source: IOM (Institute of Medicine), 2012, Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press 4
5 Substantiating Reduced Risk: Totality of Scientific Evidence Post-Market Studies and Surveillance Consumer Perception and Behavior Assessment Clinical Trials Systems Toxicology Assessment Standard Toxicology Assessment Aerosol Chemistry and Physics Product Design and Control Principles Reduced Population Harm Reduced Exposure & Risk Reduced Risk in Laboratory Models Reduced Toxicity in Laboratory Models Reduced Formation of HPHCs. HPHCs stands for Harmful or Potentially Harmful Constituents Source: Smith, M.R., et al., Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program. Regulatory Toxicology and Pharmacology (2016). 5
6 iqos: Reduced Formation Leads to Reduced Toxicity in vitro Reduced Formation Average reductions in formation of HPHCs for iqos compared to levels measured in smoke from the 3R4F reference cigarette (a) Leads to Reduced Toxicity Average reductions in toxicity compared to levels measured for the 3R4F reference cigarette 100% 3R4F 3R4F 75% 50% > 90% reduction > 90% reduction > 95% reduction > 90% reduction > 98% reduction 95% reduction 25% 0% FDA 18 (18 chemicals) PMI 58 (b) (58 chemicals) Carcinogens (c) (15 chemicals) Air Cytotoxicity (NRU) Bacterial Mutagenicity (Ames) Mammalian Mutagenicity (MLA) (a) Aerosol collection with Intense Health Canada s Smoking Regime: 55 ml puff volume, 2-second puff duration, 30-second interval puff. Comparison on a per-stick basis. Reduction calculations exclude Nicotine, Glycerin and Total Particulate Matter (b) The PMI 58 list includes the FDA 18 and (c) the 15 carcinogens of the IARC Group 1. These data alone do not represent a claim of reduced exposure or risk Source: PMI Research & Development Air 6
7 iqos: Impact on Disease Endpoints in Mouse Model of Disease Emphysema Score 4 Disease Endpoint for COPD Lung Emphysema (After 8 months) Plaque volume (mm 3 ) 1.5 Disease Endpoint for CVD Atherosclerotic Plaque (After 8 months) R4F Cessation Switching Air iqos 0 3R4F Cessation Switching Air iqos. These data alone do not represent a claim of reduced exposure or reduced risk. COPD is chronic obstructive pulmonary disease. CVD is cardiovascular disease. Switching is switching to iqos Source: PMI Research & Development 7
8 iqos: Three-Month Reduced Exposure Study (Japan) 0 o-tol 1-OHP % Reduction in Biomarkers of Exposure After Switching for Three Months 3-HPMA iqos vs. Cigarette Cessation vs. Cigarette Total NNAL HEMA HMPMA COHb B[a]P 4-ABP CEMA NNN 2-NA S-PMA MHBMA 1-NA (20) (40) (60) (80) (100) (41) (32) (48) (45) (46) (61) (77) (85) (55)(56) (50)(48) (48)(47) (67)(66) (76) (79) (91)(90) (71) (94) (85) (82) (87) (87) (81) (81) (94)(92). These data alone do not represent a claim of reduced exposure or reduced risk Source: PMI Research & Development 8
9 iqos: Three-Month Reduced Exposure Study (U.S.) 0 o-tol 1-OHP % Reduction in Biomarkers of Exposure After Switching for Three Months 3-HPMA iqos vs. Cigarette Cessation vs. Cigarette Total NNAL HEMA HMPMA COHb B[a]P 4-ABP CEMA NNN 2-NA S-PMA MHBMA 1-NA (20) (40) (60) (80) (100) (57) (61) (34) (42) (48) (65) (65) (74) (62) (50) (50)(52) (48) (53) (53) (57) (72) (72) (83) (86) (82) (93) (78) (81) (81) (84) (81) (71) (86) (89). These data alone do not represent a claim of reduced exposure or reduced risk Source: PMI Research & Development 9
10 Clinical Evidence for Reduced Risk (Japan and U.S.) Latest Results on Clinical Risk Markers Disease Mechanisms Lipid Metabolism Marker Expected Direction of Change Japan THS versus CC U.S. THS versus CC Direction of Change HDL-C 4.53 mg/dl 1.40 mg/dl Inflammation WBC GI/L 0.17 GI/L Airway Impairment Endothelial Dysfunction FEV % pred 0.5 % pred sicam-1 8.7% 10.6% Oxidative Stress 8-epi-PGF 2α 12.7% 13.5% Clotting 11-DTX-B 2 5.4% 3. 6%. These data alone do not represent a claim of reduced exposure or reduced risk Source: PMI Research & Development 10
11 iqos: Adult Consumer Perception and Behavior Assessment Measuring risk perception, comprehension, intention to use and actual use of iqos in a pre-market setting Summary of U.S. study results: - Less than 5% of adult former smokers and less than 1% of adult never smokers expressed an intention to use iqos - Adult consumers correctly understood the modified risk communications, including that iqos is not without risk - A sizable proportion of adult smokers predominantly or exclusively used iqos Post-market cross-sectional studies conducted in Japan and Italy, confirmed that relapse and initiation were below 2% and 1%, respectively 11
12 iqos: U.S. FDA PMTA & MRTPA Filing Status PMI to file applications with the U.S. FDA under FD&C Act sections 910 and 911: (PMTA) authorization required for products not on the market as of February (MRTPA) authorization to market products with modified risk claims The totality of the evidence assembled supports the potential reduced risk and population health benefit of the product Preparations for filing are well underway and we are on-track to file the MRTPA by the end 2016 and the PMTA in early
13 iqos: Long-Term Clinical Studies Smoking Cessation Response Study (12 months): - Measures changes in clinical risk markers in smokers who quit for 12 months - Study conducted in the U.S., the U.K., Poland, Germany and Japan with over 1,100 participants - Top-line results for first 6 months expected by Q3, 2017, full 12 months by Q1, 2018 Exposure Response Study (6 months + 6 months): - Measures changes in clinical risk markers in adult smokers who switch to iqos - Study conducted in the U.S. and involves close to 1,000 participants - Top-line results for first 6 months expected by Q2, 2017, additional 6 months by Q1, 2018 Source: PMI Research & Development 13
14 iqos: Reduced Impact on Oral Hygiene 1 Exposure results after 3 weeks Composite (C) Disks Baseline iqos 3R4F Spectrophotometric Score iqos 3R4F Exposure to iqos aerosol did not induce clinically significant (a) discoloration of the most widely used dental composite in this experimental setup (a) A Spectrophotometric Score > 3.3 is clinically significant Source: PMI Research & Development 14
15 iqos: Reduced Impact on Oral Hygiene 1 2 Exposure results after 3 weeks Composite (C) Disks Baseline iqos 3R4F Premolar Teeth Baseline iqos 3R4F Enamel E Composite C Dentin D Spectrophotometric Score iqos 3R4F iqos 3R4F iqos 3R4F iqos 3R4F E C D Exposure to iqos aerosol did not induce clinically significant (a) discoloration of the most widely used dental composite (C) and dental hard tissue (Enamel and Dentin) in this experimental setup (a) A Spectrophotometric Score > 3.3 is clinically significant Source: PMI Research & Development 15
16 iqos: Scientific Substantiation Progress Totality-of-Scientific Evidence Supporting Reduced Risk Potential Reduced Impact on Users and Those Around Them Improved Oral Hygiene No combustion Reduced HPHC formation Reduced toxicity Reduced exposure Reversal of clinical risk markers Pre-market PBA Less smell No ash No risk of burning No negative impact on indoor air quality Better breath Less unpleasant after taste Reduced tooth discoloration 16
17 iqos: PMI s Post-Market Assessment Assess the impact of iqos on population harm reduction Surveys and surveillance to: - Understand who uses iqos and how it is being used - Measure the prevalence of iqos use - Monitor spontaneous health events (safety surveillance) Cohort study initiated in Japan to: - Monitor how adult consumers use iqos over time - Evaluate the effect of prolonged iqos use on exposure to HPHCs and clinical risk markers 17
18 Population Health Impact The Harm Reduction Equation Population Harm Reduction = x Reduced-Risk Products Product Adoption and Usage 18
19 Population Health Impact Modelling The Harm Reduction Equation Population Harm Reduction = x Reduced-Risk Products Product Adoption and Usage The Population Health Impact Model (a) : Mortality Impact Estimates Epidemiological Risk Component Prevalence Component Simulator (a) Weitkunat R et al., A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product. Regulatory Toxicology and Pharmacology (2016). 19
20 Platform 2: Reduced Formation Leads to Reduced Toxicity in vitro Reduced Formation Leads to Reduced Toxicity Average reductions in formation of HPHCs for Platform 2 compared to levels measured in smoke from the 3R4F reference cigarette (a) Average reductions in toxicity compared to levels measured for the 3R4F reference cigarette on a per stick basis 100% 3R4F 3R4F 75% 50% > 95% reduction > 90% reduction > 95% reduction > 90% reduction No doseresponse in P2 contrary to 3R4F > 85% reduction 25% 0% FDA 18 (18 chemicals) PMI 58 (b) (58 chemicals) Carcinogens (c) (15 chemicals) Air Cytotoxicity (NRU) Bacterial Mutagenicity (Ames) Mammalian Mutagenicity (MLA) Air (a) Aerosol collection with Intense Health Canada s Smoking Regime: 55 ml puff volume, 2-second puff duration, 30-second interval puff. Comparison on a per-stick basis. Reduction calculations exclude Nicotine, Glycerin and Total Particulate Matter (b) The PMI 58 list consists of 54 HPHCs and includes the FDA 18 and (c) the 15 carcinogens of the IARC Groups 1, 2A and 2B. Reductions are calculated on 54 HPHCs. These data alone do not represent a claim of reduced exposure or reduced risk Source: PMI Research & Development 20
21 Platform 2: Reduced Exposure Study (Poland) % Reduction in Biomarkers of Exposure After Switching to Platform 2 for Five Days vs. % Reduction in Biomarkers of Exposure After Cessation P2 vs. Cigarette Cessation vs. Cigarette (a) 0 o-tol Total 1- OHP 3-HPMA Total NNAL HEMA HMPMA COHb B[a]P 4-ABP CEMA NNN 2-NA S-PMA MHBMA 1-NA (20) (40) (60) (80) (100) (72) (56) (64) (58) (65) (76) (59) (77) (79) (a) Cessation data referenced is from the five-day Reduced Exposure Study carried out for iqos in Poland. These data alone do not represent a claim of reduced exposure or reduced risk Source: PMI Research & Development (86) (70) (90) (88) (83) (97) 21
22 Platform 2: Reduced Exposure Clinical Study (Poland) Nicotine Equivalents and Urge-to-Smoke Index After Switching to Platform 2 for Five days vs. a Cigarette Platform 2 Cigarette 16 Nicotine Equivalents (ng/mg creatinine) 7 Urge-to-Smoke Index (Total score) Baseline Day 1 Day 2 Day 3 Day 4 Day 5 0 Baseline Day 1 Day 2 Day 3 Day 4 Day 5 Note: Urge-to-Smoke index is on a seven-point scale. Reduced-Risk Products ("RRPs") is the term the company uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. These data alone do not represent a claim of reduced exposure or reduced risk Source: PMI Research & Development 22
23 Platform 3: Clinical Assessment Pharmacokinetic study completed in New Zealand at the end of Q2, 2016 Pharmacodynamics study ongoing in the U.S., results by end 2016 Six month safety and efficacy study conducted in 2017 N ic o tin e p la s m a c o n c e n tra tio n Nicotine Blood Plasma Concentration (ng/ml ± 95% CI) (n g /m L 9 5 % C I) Nicotine Pharmacokinetic Profile T im e (m in ) P la tfo rm 3 C ig a re tte Note: Platform 3 pharmacokinetic study ClinicalTrials.gov identifier NCT A representative example of the pharmacokinetic profile after single-use of a conventional cigarettes is shown (taken from a study conducted in the UK [ClinicalTrials.gov identifier NCT ]). Reduced-Risk Products ("RRPs") is the term the company uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. These data alone do not represent a claim of reduced exposure or reduced risk Source: PMI Research & Development 23
24 Platform 4: Assessment Program and Progress Current E-vapor Product Portfolio Pre-clinical assessments completed: - Aerosol chemistry - Aerosol toxicity in vitro and in vivo Indoor air quality assessment completed Next Generation E-vapor Products Clinical Assessments planned: Pharmacokinetic study in 2016 Reduced exposure study in
25 RRPs: Independent Verification of PMI s Results (Strategy) Independent Studies Studies conducted by independent scientists Crowd-Sourced Verification Verification of methods and results using crowd-sourcing (sbvimprover.com) Expert Reports Verification of specific datasets Publish Study Results Peer-reviewed articles in scientific literature 25
26 RRPs: Scientific Substantiation Summary Totality-of-the-Scientific-Evidence on iqos demonstrates the risk reduction potential to individual adult smokers and the potential to reduce population harm compared to cigarette smoking On track to file MRTPA with the U.S. FDA for iqos by the end of PMTA in Q1, 2017 Making significant progress on other RRP platforms Further information about our science can be found on PMIScience.com 26
27 Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Mirek Zielinski President, Reduced-Risk Products 27
28 Agenda Reduced-Risk Products (RRPs) Scientific Substantiation Progress RRP Regulation RRP Portfolio and Commercialization Approach 28
29 RRPs Regulation: Positive Developments Growing understanding of harm reduction and potential of RRPs driven by science and adult smoker switching Positive developments include: - Consultation on regulation of e-cigarettes in New Zealand - Reversal of pharma-only approach to e-cigarettes in several EU Member States - Adoption of regulatory frameworks for novel tobacco products in the EU - Recognition that non-combustible products differ from cigarettes - Calls for education of public, especially adult smokers, about combustion and nicotine: U.K. Royal Society for Public Health; France Public Heath Agency Increasing number of public health advocates, medical doctors, researchers Many with anti-tobacco credentials 29
30 RRPs Regulation: Landscape is Evolving Step by step: evolution as markets move towards harm reduction Concerns/opposition continues: Skepticism, stakeholder vested interests, and legitimate public health questions PMI and others are taking steps to address concerns: - Pre- and post-market research - Third parties are actively (and appropriately) studying these issues and publishing the data: Studies show that rather than acting as a gateway to smoking or nicotine use, e-cigarettes are a gateway out of smoking Statement by Public Health England (July 2016) 30
31 RRPs Regulation: Objectives PMI advocates for: Product standards for market access: - Initial positive standards already in place through EU TPD notification requirements Differential marketing, labelling, product and public use regulation: - Public Health England recommendations around public use of e-cigarettes Standards for risk-related claims: - Including clinical and behavioral data Requirements for manufacturers to provide pre- and post-market information regarding the impact of products on population harm 31
32 RRPs Regulation: Taxation PMI advocates for a sensible approach to novel products with groundbreaking potential Unique product characteristics of heat-not-burn (non-cigarette): - Design characteristics (construction and content) - Scientific studies (PMI and third party experts): absence of combustion; aerosol fundamentally different from cigarette smoke Tax and customs classifications in launch markets: - In launch markets, HeatSticks are either taxed under a dedicated new excise category or as other tobacco products ("OTP") depending on national legislation Product differentiation is a foundation for tax-based on risk reduction - Rationale supported by harm reduction advocates: Differential Taxes for Differential Risks Toward Reduced Harm from Nicotine-Yielding Products, New England Journal of Medicine (August 2015) - Contingent upon clear scientific substantiation of risk reduction 32
33 RRPs Portfolio: Our Approach iqos (Platform 1) City Tests National Geographic Expansion Platform 2 Final Phase of Development Clinical Trials City Test Platform 3 Product Development City Test Platform 4 (current generation) Nicocigs Acquisition Commercialization in Selected Geographies Platform 4 (next generation) Heated Tobacco Products E-Vapor Joint Research, Development & Technology Sharing Agreement with Altria Nicotine-Containing Products Commercialization 33
34 iqos: Commercialization Approach Optimization Optimize route-to-adult consumer strategies: - Focus on full conversion - Understanding of the offer and commitment to convert - Conversion support - Product and category benefits communication - Retail experience - Digital marketing and communication of category and offer Optimize and enhance product offer Campaign focus to increase understanding of the difference between combusting and heating tobacco 34
35 iqos: Conversion in Japan Converted Users and Cost per New Converted User Index First Tried iqos With a Friend 100 Converted Users (in thousands) Cost per Converted New User Index % 17% Q3 Q4 Q1 Q2 August Q Q Source: PMI Financials or estimates, PM Japan iqos User Panel 35
36 iqos: Device Penetration Ratio Performance 10% Device Cumulative Weekly Offtake Penetration Ratio (2016) 9.5 Japan 8% 7.0 6% Capacity constraints / Supply cap 4% Switzerland 2% 0% January March June September Lisbon Italy Bucharest Moscow. Italy refers to the Expansion Area (Bologna, Milan, Modena, Rome and Turin). Switzerland refers to the Launch Area (Basel, Bern, Geneva, Lausanne, Neuchâtel and Zurich). Visuals are for illustrative purposes only Source: PMI Financials or estimates 36
37 iqos: Conversion Performance Converted and Predominant User Share (July 2016) Converted ( 95% iqos) 65% 52% 49% 58% 53% 54% Predominant (70%-95% iqos) 16% 17% 13% 14% 14% 8% (a) Japan Italy Switzerland Romania Russia Portugal (a) Data relates to August User Panel Source: PMI Japan / Italy / Switzerland / Romania / Russia / Portugal iqos User Panels 37
38 iqos: HeatSticks Offtake Volume Performance 800 (Index) Weekly Indexed Offtake Volume Performance (2016) (4-week moving average) Japan Lisbon January March June September Italy Moscow Switzerland Bucharest. Italy refers to the Expansion Area (Bologna, Milan, Modena, Rome and Turin). Switzerland refers to the Launch Area (Basel, Bern, Geneva, Lausanne, Neuchâtel and Zurich). Pack designs are for illustrative purposes only Source: PMI Financials or estimates 38
39 iqos: Performance in Japan HeatSticks Offtake and IMS Shares and iqos Offtake Penetration Ratio Offtake SoM (National) IMS Weekly SoM (National) Penetration Ratio (National) 10.00% 9.00% 8.00% 7.00% 6.00% 5.00% 4.00% 3.00% 2.00% 1.00% 0.00% 1.6% 0.5% 3.2% 1.1% 0.4% 1.0% 7.0% 2.7% 2.6% 9.5% 4.1% 4.3% Q4 Q1 Q2 QTD Sept National market share represents the total sales volume for HeatSticks as a percentage of the total estimated sales volume for cigarettes and HeatSticks. Offtake share represents C-stores sales volume for HeatSticks as a percentage of the total actual retail sales volume for cigarettes and HeatSticks. Pack designs and visuals are for illustrative purposes only Source: PMI Financials or estimates, and Tobacco Institute of Japan 39
40 iqos: Performance in Italy and Switzerland HeatSticks Offtake Share and iqos Offtake Penetration Ratio Offtake SoM (Launch Area) Offtake SoM (National) Penetration Ratio (Launch Area) Penetration Ratio (National) Italy Switzerland 3.7% 4.5% 0.4% 0.2% 0.1% 0.7% 0.3% 0.1% 1.3% 0.6% 0.3% 0.1% Q4 Q1 Q2 QTD Sept Launch Area refers to the Expansion Area in Italy (Bologna, Milan, Modena, Rome and Turin) and the Launch Area in Switzerland (Basel, Bern, Geneva, Lausanne, Neuchâtel and Zurich) Source: PMI Financials or estimates 1.8% 0.5% 0.6% 2.6% 0.7% 0.9% 0.9% 1.3% 1.1% 1.6% 0.2% 0.2% 0.3% 0.4% Q4 Q1 Q2 QTD Sept
41 iqos: Performance in Moscow and Bucharest HeatSticks Offtake Share and iqos Offtake Penetration Ratio HeatSticks Offtake SoM iqos Offtake Penetration Ratio Moscow Bucharest 1.2% 0.6% 0.7% 0.3% 0.1% 0.1% 0.3% 0.1% 0.2% 0.2% 0.1% 0.4% 0.1% 0.2% Q4 Q1 Q2 QTD Sept Q4 Q1 Q2 QTD Sept Source: PMI Financials or estimates 41
42 iqos: Performance in Lisbon and Monaco HeatSticks Offtake Share and iqos Offtake Penetration Ratio HeatSticks Offtake SoM iqos Offtake Penetration Ratio 1.40% 1.20% 1.00% Lisbon 1.4% 0.3% 0.50% % 0.04 Monaco 5.0% 3.8% 5.0% 4.0% 0.80% 0.7% 0.30% % 3.0% 0.60% 0.40% 0.20% Q4 15 Q1 16 Q2 16 Aug % 0.5% 0.1% 0.2% 0.20% % % 1.2% 2.0% 1.0% 0.00% Q Q1 Q QTD Sept 0.00% 0 Q Q1 Q2 QTD Sept % Source: PMI Financials or estimates 42
43 iqos: Performance in Frankfurt HeatSticks Offtake Share and iqos Offtake Penetration Ratio HeatSticks Offtake SoM iqos Offtake Penetration Ratio Frankfurt % % Q Q1 Q2 QTD Sept Source: PMI Financials or estimates 43
44 iqos: Product and Category Benefits Communication Substantiated and prioritized messages will be deployed in line with local laws and regulations Examples of current messages deployed: - Real tobacco taste & satisfaction (all markets) - Convenience (no ash, less smell, no risk of fire) (all markets) - No negative impact on indoor air quality (Japan, Russia) - Reduced formation of HPHCs (Japan, Russia) - Short term benefits: Better breath (Romania, Switzerland) Less unpleasant aftertaste (Switzerland) 44
45 iqos: Retail Experience Flagship Store: - iqos brand expression - Location for guided trial & product experiences - Adult consumer engagement, community space and events - Customer care infrastructure Scalable formats with consistent global look and feel: - Flagship stores, boutiques and pop-ups Located in launch markets key urban areas Will be for all our RRP portfolio 45
46 iqos: Digital Communication and Marketing Digital tools to support awareness, conversion and sharing: Mobile App: - Accompany adult smokers through conversion from cigarettes to iqos and HEETS - Q4, 2016 test in Japan and Switzerland iqos global website under development: - Full integration of e-commerce, local events information, online product tutorials. Visuals are for illustrative purposes only 46
47 iqos: New Device Product Improvements: - Aesthetics - Improved User Interface - Faster Charging - Bluetooth Connectivity - Mobile App iqos 2.4Plus iqos
48 iqos: New Device and Accessories Accessories Soft Leather Pouches Colored Caps 48
49 RRPs: Portfolio Brand Architecture THE SCIENCE "iqos HeatControl Technology THIS CHANGES EVERYTHING" BRAND PLATFORMS CONSUMABLES TM TM TM TM 49
50 50
51 iqos: Mobility Kit. Visual execution is for illustrative purposes only 51
52 HEETS Line-Up. Pack designs are for illustrative purposes only 52
53 . Visual execution is for illustrative purposes only 53
54 . Visual execution is for illustrative purposes only 54
55 . Visual execution is for illustrative purposes only 55
56 . Visual execution is for illustrative purposes only 56
57 . Visual execution is for illustrative purposes only 57
58 Platform 2: TEEPS Four-week whole offer test conducted in Romania at the end 2015: - Better-than-expected adult smoker feedback 60% predominant use City test in 2017 Relevant accessories for lighting and extinguishing developed. The product depicted is subject to ongoing development and therefore visuals are illustrative and do not necessarily represent the latest stages of product development Source: PMI Market Research 58
59 Platform 4: MESH Technology MESH vaporization technology: - HeatControl Technology - Consistent vapor delivery - Low liquid detection - Puff activation - "Closed" system - Manufacturing automation MESH PRE-FILLED CAPSULE ACTIVATION BUTTON BATTERY. The product depicted is subject to ongoing development and therefore visuals are illustrative and do not necessarily represent the latest stages of product development 59
60 Platform 4: MESH Technology City Test Q4, 2016 U.K. city test of the new technology and product offer through Nicocigs Ltd. MESH: brand name chosen for city test 4 new unique and complex flavor offers being tested Learnings will help refine product offer for national roll-outs. Visual is for illustrative purposes only 60
61 RRPs: Capacity Outlook In support of our commercial launches, we are scaling up capacity for iqos devices and HeatSticks as well as customer care infrastructure The construction of our first dedicated RRP Greenfield factory in Bologna, Italy, has been completed As the commercialization of our RRPs expand, we will initiate further Greenfield expansions as well as integrate HeatSticks production into existing PMI manufacturing facilities 61
62 Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Video (not shown on webcast)
63 RRPs: PMI Published Patents Rapidly increasing RRP IP portfolio of granted patents and pending applications Extensive coverage protecting a broad range of inventions, from tobacco substrate to aerosol generation and control, to manufacturing process and device Majority of our patents have a lifetime beyond 2030 >50% of our patent portfolio is related to iqos technologies: - Acceleration of patent filing as of ,000 3,500 3,000 2,500 2,000 1,500 1, PMI RRP Published Patents Worldwide (a) Granted Pending (a) Status at August 15, 2016 Source: PMI Research & Development 63
64 RRPs: Summary PMI with market-leading RRP portfolio: - Strong iqos performance momentum - City test of Platform 2 in City test of Platform 3 in City test of our new Mesh heating technology in the U.K. by end of 2016 Performance from optimized iqos marketing and commercialization model exceeding expectations in Japan. Deployment of new model in other markets showing encouraging offtake volume performance results Solid progress on harm reduction substantiation and third party verification of science Increasing awareness of the harm reduction potential of Reduced-Risk Products among regulators and the scientific community 64
65 RRPs: Program Outlook Increase geographical coverage of iqos in existing launch markets iqos present in key cities in more than 30 markets by end 2017, representing an industry volume in excess of 1 trillion units Target 3% to 5% share of markets in scope, net of cannibalization Expect to be profitable by 2018 Our ambition is to convince all adult smokers that intend to continue smoking to switch to RRPs as soon as possible Our intention is to continue to lead the cigarette category and become the undisputed leader in RRPs Source: PMI Financials or estimates 65
66 Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Video (not shown on webcast)
67 Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Questions & Answers 67
The importance of offering adult smokers a portfolio of potentially less harmful products
The importance of offering adult smokers a portfolio of potentially less harmful products International Symposium on Nicotine Technology June 15 th 2017 Thomas Mc Grath, PhD PMI R&D, Philip Morris Products
More informationHeated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences
Heated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences Global Forum on Nicotine 2017 Moira Gilchrist PhD Philip Morris International June 16th 2017 Important Information Reduced-Risk
More informationRemarks by. Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products. Mirek Zielinski President, Reduced-Risk Products
Remarks by Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products Mirek Zielinski President, Reduced-Risk Products Philip Morris International Inc. Investor Day Lausanne, September 29, 2016 We
More informationTobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment
Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment Global Forum on Nicotine 2016 Moira Gilchrist PhD Philip Morris International R&D June 17th
More informationHeat-not-Burn Products: Scientific Assessment of Risk Reduction
Heat-not-Burn Products: Scientific Assessment of Risk Reduction Tobacco Merchants Association 2015 Annual Meeting Moira Gilchrist PhD Philip Morris International R&D May 20th 2015 The Objective is Harm
More informationInvestor Day Lausanne, September 27, 2018
Investor Day Lausanne, September 27, 2018 Jacek Olczak Chief Operating Officer OPERATING AROUND THE ADULT CONSUMER 2 Operating Around the Adult Consumer CC RRPs PMI Combustible Cigarette Performance Reduced-Risk
More informationAssessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data
Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data Global Forum on Nicotine 2015 Bruce D. Clark PhD Philip Morris International
More informationHow innovation will deliver a smokefree
How innovation will deliver a smokefree future Innovation and Good Practices in the Health Sector Rui Minhos Head of Regional Scientific Engagement Philip Morris International 6th November 2018 Our contact
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationTOBACCO HARM REDUCTION:
TOBACCO HARM REDUCTION: An Overview of PMI s Scientific Approach & Main Results for the Tobacco Heating System (THS) 2.2, a Candidate Modified Risk Tobacco Product Tunis, Tunisia Dr. Nuno Fazenda, on behalf
More informationChanges in Biological and Functional Markers after Six Months, in Three Populations: THS 2.2 (IQOS ) Users, Continued Smokers, and Smoking Abstinence
Changes in Biological and Functional Markers after Six Months, in Three Populations: THS 2.2 (IQOS ) Users, Continued Smokers, and Smoking Abstinence Christelle Haziza, PhD Manager Clinical Science Philip
More informationCARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING
CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING Athens, Greece Dr. Patrick Picavet, M.D., on behalf of: Baker, Gizelle; Haziza, Christelle; Hoeng, Julia;
More informationCARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING
CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING Athens, Greece Dr. Patrick Picavet, M.D., on behalf of: Baker, Gizelle; Haziza, Christelle; Hoeng, Julia;
More informationThe IQOS Heating System
The IQOS Heating System Tobacco Products Scientific Advisory Committee January 24, 2018 CC-1 Introduction Moira Gilchrist, PhD Vice President Scientific and Public Communications Philip Morris International
More informationInvestor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region
Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional
More informationBiomarker of Exposure Reductions Upon Switching for 5 Days from Cigarettes to a Carbon Heated Tobacco Product (CHTP 1.0)
Biomarker of Exposure Reductions Upon Switching for Days from to a Carbon Heated Tobacco Product () A. Donelli, C. Tran, C. Haziza, J. Ancerewicz, G. de La Bourdonnaye, R. Weitkunat, and F. Lüdicke 8 healthy
More informationThe IQOS Heating System
The IQOS Heating System Tobacco Products Scientific Advisory Committee January 24, 2018 CC-1 Introduction Moira Gilchrist, PhD Vice President Scientific and Public Communications Philip Morris International
More informationIndustry Post-Regulation. E-Cigarette Summit Tim Phillips, ECigIntelligence. 17 th November
Industry Post-Regulation E-Cigarette Summit 217 Tim Phillips, ECigIntelligence 17 th November 217 www.ecigintelligence.com Agenda 1 2 3 Post-TPD: Has regulation been a success? Heated Tobacco: a success?
More informationWhat is combustion and why is the absence of combustion important for heat not burn products
What is combustion and why is the absence of combustion important for heat not burn products Global Forum on Nicotine 2017 June 16 th 2017 Thomas Mc Grath PhD PMI R&D, Philip Morris Products S.A., Quai
More informationA study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design.
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design. Nathan Gale 1, Mike McEwan 1, Alison Eldridge 1, Neil
More informationInvestor Day Lausanne, September 27, 2018
Investor Day Lausanne, September 27, 2018 André Calantzopoulos Chief Executive Officer PMI: Strong Business with a Strong Future Enormous opportunity from RRPs is undiminished Our goal: convincing people
More informationReduced-Risk Products Science Update
Reduced-Risk Products Science Update Dr. Ian Jones, PhD JTI VP, Reduced-Risk Products Science Forward-Looking Statements This presentation contains forward-looking statements. These statements appear in
More informationInvestor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free
Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars
More informationActual Use Study of the Potential Reduced-Risk Product (RRP): Tobacco Heating System (THS)
Actual Use Study of the Potential Reduced-Risk Product (RRP): Tobacco Heating System (THS) S. Roulet 1, P. Magnani 1, G. Kallischnigg 2, A. Dugan 3, C. Gage 3, C. Kanitscheider 4, M. Apecechea 4, A. Ramazzotti
More informationThe IQOS Heating System
Script and Slides of Philip Morris International s Presentation before the Tobacco Products Scientific Advisory Committee (TPSAC) 24 January 2018 Slide 1 The IQOS Heating System Tobacco Products Scientific
More informationInvestor Day EU Region Lausanne, June 26, Drago Azinovic President, European Union Region Philip Morris International
Investor Day EU Region Lausanne, June 26, 2014 Drago Azinovic President, European Union Region Philip Morris International Agenda Strong Business Fundamentals Strategies for Growth Key Markets Concluding
More informationCommunication on Progress 2016 United Nations Global Compact
Communication on Progress 2016 United Nations Global Compact Key facts about Philip Morris International Inc. (PMI) Company footprint 180 Countries where PMI operates 48 Production facilities in 32 countries
More informationInvestor Day Lausanne, June 21, André Calantzopoulos Chief Operating Officer Philip Morris International
Investor Day Lausanne, June 21, 2012 André Calantzopoulos Chief Operating Officer Philip Morris International Agenda Industry Overview Competitive Landscape Fiscal & Regulatory Environment Regional Overview
More informationInvestor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications
Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available
More informationJT Group Consolidated Financial Results 2018 First Quarter Results
JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown
More informationJUUL and Other Emerging Tobacco Products. Emily McClelland, M.S. December 6, 2018
JUUL and Other Emerging Tobacco Products Emily McClelland, M.S. December 6, 2018 7.2% for high school students 1.5% for middle school students Preliminary 2018 National Youth Tobacco Survey Findings Surge
More informationAnalysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan
Analysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan A van der Plas, L Prieto, D Skiada, M Dobrynina, G Baker, F Ludicke PMI R&D, Philip Morris
More informationBuilding Capacity for Tobacco Dependence Treatment in Japan. Request for Proposals (RFP) - Background and Rationale
Building Capacity for Tobacco Dependence Treatment in Japan Request for Proposals (RFP) - Background and Rationale Geographic Scope Japan Application process This application process has two steps: Letters
More informationUPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY
UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY Presented by Ii-Lun Chen, M.D Director Division of Individual Health Science Office of Science, CTP, FDA Disclaimer: This is not a formal dissemination
More informationFDLI Annual Conference
FDLI Annual Conference Panel Tobacco Harm Reduction: Opportunities & Regulatory Pathways to Achieve May 5, 2017 Joe Murillo Vice President, Regulatory Affairs Altria Client Services Panel Discussion at
More informationMight Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re
Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re 2 Agenda Smoking is still a problem Stopping is hard Electronic cigarettes Reduced Risk tobacco products Males >15yr
More informationThe concept that not all tobacco and nicotine products
A Model Risk Continuum for Tobacco and Nicotine Products by Chris Proctor, Sudhanshu Patwardhan, and James Murphy The concept that not all tobacco and nicotine products present the same risks to human
More informationVontobel Viewpoints FDA New Direction on Tobacco Our Take
Quality Growth Boutique TM Vontobel Viewpoints On July 28, 2017, the new Commissioner of the U.S. Food and Drug Administration (FDA), Scott Gottlieb, surprised the markets by launching a consultation paper
More informationPolicy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: (name) Philip Hope / Assoc Prof Chris Atkinson Address: (street/box number)
More informationShould FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how?
Should FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how? Jeff Weiss General Counsel/EVP of Gov. Affairs of NJOY, LLC FDLI - October 20, 2017 FDA s
More informationGlobal E-Cigarette Market- Industry Analysis & Outlook ( )
Global E-Cigarette Market- Industry Analysis & Outlook (2016-2020) ----------------------------------------- Executive Summary Electronic cigarettes, also known as E-cigarettes, electronic nicotine delivery
More informationAN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE
AN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE Mitch Zeller, J.D. Director, FDA May 3, 2018 CENTER FOR TOBACCO PRODUCTS HOW CAN WE MAKE THE GREATEST IMPACT? We truly find ourselves at a
More informationTowards a Smokefree Generation: A Tobacco Control Plan for England. Tim Baxter, Department of Health, England
Towards a Smokefree Generation: A Tobacco Control Plan for England 1 Tim Baxter, Department of Health, England Smoking rates are falling fast... 25 Adult Smoking prevalence in England (daily and non daily)
More informationSmoking and Non-Communicable Diseases in Hong Kong
Smoking and Non-Communicable Diseases in Hong Kong Current Status and the Way Forward Prof. David Khayat Former Head of Medical Oncology at the Pitié-Salpêtrière in Paris Former President of the National
More informationWhy comprehensive TC is essential for successful harm reduction
Why comprehensive TC is essential for successful harm reduction E-cigarette summit London 15 th November 2018 Deborah Arnott Chief Executive ASH (Action on Smoking and Health) Declaration of Interest ASH
More informationAnnual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018 Árpád Könye Chairman of the Board of Directors Total Cigarette Market Czech Republic Total cigarette market down
More informationGLOBAL TOBACCO REGULATION OVERVIEW IVAN GENOV RESEARCH ANALYST 31 MAY 2018
IVAN GENOV RESEARCH ANALYST 31 MAY 2018 Three tiers of regulations affecting the industry 2 Core Advertising and sponsorship bans Descriptor bans Tax-driven excise increases Standard Public smoking bans
More informationAir Quality assessment during indoor use of the Tobacco Heating System 2.2
Air Quality assessment during indoor use of the Tobacco Heating System 2.2 THS 2.2. is commercialized under the IQOS brand name Dr Catherine Goujon Ginglinger - Philip Morris International Research & Development,
More informationSmoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017
Smoking, e-cigs and reduced risk products Dr John Schoonbee, IMS November 2017 2 The storyline smoking is bad yet many folks still smoke because quitting is very hard is it better, if one cannot quit,
More informationSustainability Report 2017
Sustainability Report 2017 1 Philip Morris International Sustainability Report 2017 1 About PMI Philip Morris International Inc. (PMI) is a leading international tobacco company with a diverse workforce
More informationNext Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21
Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21 st October 2015 Contents Evolution of products across
More informationResponsible Practice in E-Vapour Products (EVP) Product Stewardship
Responsible Practice in E-Vapour Products (EVP) Product Stewardship Tanvir Walele, MSc, ERT 11 October 2016 1 Responsible Practice Responsible practice can be divided in to 3 areas: Pre-market product
More informationExploring five common claims about e-cigarette use. Lion Shahab, PhD University College
Exploring five common claims about e-cigarette use Lion Shahab, PhD University College London @LionShahab Claim 1: Renormalisation Claim 1: Renormalisation A priori predictions for impact on population
More informationThe English experience in a European regulatory context. E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK)
The English experience in a European regulatory context E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK) Declaration of Interest ASH (UK) is a public health charity
More informationModelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery
Global Nicotine Forum 2018 Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery Ed Stephens University of St Andrews Declaration: No conflicts of interest
More informationScientific Evidence for Evaluating Modified Risk Tobacco Products
Scientific Evidence for Evaluating Modified Risk Tobacco Products Presented to the IOM Committee on Scientific Standards for Modified Risk Tobacco Products May 9 th 2011, Washington DC 1 l Altria Client
More informationPROCEDURE FOR GENERATION AND TESTING OF MAINSTREAM TOBACCO HEATING SYSTEM (THS or IQOS) AEROSOL USING A LINEAR SMOKING MACHINE
PROCEDURE FOR GENERATION AND TESTING OF MAINSTREAM TOBACCO HEATING SYSTEM (THS or IQOS) AEROSOL USING A LINEAR SMOKING MACHINE 1 P age Table of contents / Table des matières 1 Introduction...3 1 Scope...3
More informationFDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES
FDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES Mitch Zeller, J.D. (Director, FDA CTP) Matthew R. Holman, Ph.D. (Director, Office of Science, FDA CTP) Kathy Crosby
More informationΕΝΑΛΛΑΚΤΙΚΕΣ ΜΟΡΦΕΣ ΚΑΠΝΙΣΜΑΤΟΣ
ΕΝΑΛΛΑΚΤΙΚΕΣ ΜΟΡΦΕΣ ΚΑΠΝΙΣΜΑΤΟΣ E CIGARETTE ENDS:ELECTRONIC NICOTINE DELIVERY S Y S TEM) ΗΕΑΤ-ΝΟΤ-ΒURN CIGARETTES (IQOS) Κουρέα Καλλιρρόη Καρδιολόγος NICOTINE DELIVERY SYSTEMS NICOTINE DELIVERY SYSTEMS
More informationFDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update
FDLI s Enforcement, Litigation, and Compliance Conference Center for Tobacco Products Office of Compliance and Enforcement 2017 Update Ann Simoneau, Director Office of Compliance and Enforcement Center
More informationEvaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Aerosol System
Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Aerosol System A. Teichert 1, P. Brossard 1, L. Felber Medlin 1, L. Sandalic 1, J. Ancerewicz 1, M. Franzon
More informationRE: Docket No. FDA-2014-N , Electronic Cigarettes and the Public Health
VIA ELECTRONIC SUBMISSION June 30, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 RE: Docket No. FDA-2014-N-1936-0001, Electronic
More informationPhilip Morris International s Position Statement on the Revision of the Tobacco Excise Directive. 14 February 2017
Philip Morris International s Position Statement on the Revision of the Tobacco Excise Directive 14 February 2017 1 Contents Introduction... 3 Revision of the Tobacco Excise Directive... 4 Scope of the
More informationA proposed bridging approach for the assessment of novel tobacco products
A proposed bridging approach for the assessment of novel tobacco products Dr. Ian M. Fearon British American Tobacco (Investments) Limited R&D Centre Southampton, U.K. Agenda Insight into BAT R&D Evolution
More informationTexas Bill to Regulate Vapor Products. Over the past few years, electronic cigarettes, also commonly referred to as e-cigarettes
Texas Bill to Regulate Vapor Products Over the past few years, electronic cigarettes, also commonly referred to as e-cigarettes or vapor, have been trending all over the state of Texas as a tobacco alternative,
More informationModified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective
Modified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective Patricia I. Kovacevic General Counsel, Chief Compliance Officer Presentation to the Food and Drug Law Institute Tobacco Conference,
More informationThe Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))
The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) January 12, 2011 Cristi Stark, MS Senior Regulatory Health Project Manager Office
More informationThe Global Network Aiming to deliver safe quality care in relation to tobacco for every service user, every time and everywhere
The Global Network Aiming to deliver safe quality care in relation to tobacco for every service user, every time and everywhere STRATEGIC PLAN 2015 2018 Use of Terms For the purpose of Global Network the
More informationAnalysis of the Public's Perception on the Use of E- Cigarettes as an Alternative to Smoking
WRIT: GSW Journal of First-Year Writing Volume 2 Issue 1 Article 3 8-20-2018 Analysis of the Public's Perception on the Use of E- Cigarettes as an Alternative to Smoking Richard F. Marquardt II BGSU Undergraduate,
More informationMitch Zeller, Director, Center for Tobacco Products, FDA September 19, 2013 Kansas Public Health Association
Regulatory Public Laws Compliance & Education Policies Science & Enforcement & Communications The FDA Center for Tobacco Products (CTP): Its Role in Reducing Tobacco Use Mitch Zeller, Director, Center
More informationFDA s Action Agenda to Reduce Tobacco Related-Cancer Incidence and Mortality
FDA s Action Agenda to Reduce Tobacco Related-Cancer Incidence and Mortality Lawrence Deyton, M.S.P.H., M.D. Director, FDA Center for Tobacco Products June 11, 2012 FDA s Vision To make tobaccorelated
More informationDetailed analysis of the Executive Summary (Section 2.7) submitted by Philip Morris International in support of its MRTP application for IQOS
Detailed analysis of the Executive Summary (Section 2.7) submitted by Philip Morris International in support of its MRTP application for IQOS Stanton A. Glantz, Ph.D. and Lauren K. Lempert, JD, MPH UCSF
More informationHealth (Tobacco, Nicotine etc. and Care)(Scotland) Bill. Japan Tobacco International (JTI)
Health (Tobacco, Nicotine etc. and Care)(Scotland) Bill Organisation name Japan Tobacco International (JTI) Japan Tobacco International (JTI) is part of the Japan Tobacco group (JT Group) of companies,
More informationCardiovascular effects of nicotine vs. cigarette smoke
Cardiovascular effects of nicotine vs. cigarette smoke Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece National School of Public Health, Athens-Greece
More informationEvaluating Interventions to Curb ENDS Use Among Utah Youth
Evaluating Interventions to Curb ENDS Use Among Utah Youth CDC CC Grant 2016-2017 Braden Ainsworth, MPH, Utah Department of Health Claudia Bohner, MPH, Utah Department of Health Erik Crankshaw, PhD, RTI
More informationFROM TOBACCO TO SOMETHING BETTER
FROM TOBACCO TO SOMETHING BETTER OUR APPROACH TO NEXT GENERATION PRODUCTS www.imperialbrandsplc.com WELCOME Imperial Brands is a dynamic fast moving consumer goods company borne out of a strong tobacco
More informationThe Voice of Local Public Health in New York State. May 12, 2014
The Voice of Local Public Health in New York State May 12, 2014 Testimony before the Senate Standing Committee on Health To consider including electronic cigarettes in the existing Clean Indoor Air Act
More informationThe Latest on Vaping Among U.S. Teens
The Latest on Vaping Among U.S. Teens Jon Macy, PhD, MPH Indiana University School of Public Health Bloomington Presentation Outline Overview of Electronic Nicotine Delivery Systems (ENDS) New Prevalence
More informationDiscussion points on Bill S-5
Disclaimer: The following document was developed to provide a brief set of discussion points for individuals wishing to discuss Bill S-5 with policy makers, politicians, senators or their advisers. It
More informationPolicy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: Address: (name) Mark Forsyth (street/box number) 3 Queens Wharf (town/city)
More informationIntroduction. Principles
NHS Health Scotland s position statement on Electronic Nicotine Delivery Systems ENDS - e-cigarettes and other smoking simulator products 31 October 2014 Introduction NHS Health Scotland is the national
More informationUPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)
UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) Mitch Zeller, J.D. Director, FDA May 4, 2017 CENTER FOR TOBACCO PRODUCTS AGENDA Update on Regulations and Guidances: Deeming Update on Science Update
More informationUNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products
UNITED STATES REGULATION OF TOBACCO PRODUCTS Presented by Mitch Zeller Center Director FDA Center for Tobacco Products May 24, 2016 OVERVIEW OF TODAY S PRESENTATION Highlights of the Deeming Final Rule
More informationHelping Smokers to Quit in General Practice
Helping Smokers to Quit in General Practice New options with Vape to Quit Vape to Quit toolkit (But don t forget prescription medications) Vape to Quit Offer this option to patients who have been unsuccessful
More informationMARKETING STANDARDS FOR MEMBERSHIP
MARKETING STANDARDS FOR MEMBERSHIP The Vapor Technology Association (VTA) is a leading national trade association in the electronic cigarette and vapor product industry. VTA represents the manufacturers,
More informationE-Cigarettes: Current Perspective
E-Cigarettes: Current Perspective Aruni Bhatnagar, Ph.D. Professor of Medicine University of Louisville Louisville, KY Electronic Cigarettes E-cigarettes are electronic nicotine delivery systems (ENDS),
More informationThe State of Smoking 2018 Global Survey Findings and Insights. Monday, March 19, 2018
The State of Smoking 2018 Global Survey Findings and Insights Monday, March 19, 2018 WELCOME 2 Dr. Derek Yach President, Foundation for a Smoke-Free World Support and Disclaimer The Foundation is an independent,
More informationMDQuit Best Practices Conference January 26, Presented by William C. Tilburg Deputy Director
MDQuit Best Practices Conference January 26, 2017 Presented by William C. Tilburg Deputy Director Founded in 2001 Partnership between UM School of Law, DHMH, and Maryland Office of the Attorney General
More informationAssessing the impact of Ploom TECH use on indoor air quality (IAQ)
Assessing the impact of Ploom TECH use on indoor air quality (IAQ) ISoNTech June 14, 2018 Dr. Ian Jones VP Reduced-Risk Products Science, JTI Reduce- Risk Products RRP Science Source reference for the
More informationEffective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products
Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Quick Facts Retailers that mix and prepare e-liquids or create or modify vaporizers
More informationMinisterial Round Table: Accelerating implementation of WHO FCTC in SEAR
REGIONAL COMMITTEE Provisional Agenda item 14.3 Sixty-eighth Session SEA/RC68/28 Dili, Timor-Leste 7 11 September 2015 20 July 2015 Ministerial Round Table: Accelerating implementation of WHO FCTC in SEAR
More informationMODIFIED RISK TOBACCO PRODUCT MARKETING DECISIONS
MODIFIED RISK TOBACCO PRODUCT MARKETING DECISIONS Presented by David Ashley, Ph.D. Rear Admiral (retired), US Public Health Service Director, Office of Science, CTP, FDA Disclaimer: This is not a formal
More informationExcise duties applied to manufactured tobacco
Ernst & Young LLP 1 More London Place London SE1 2AF Tel: + 44 20 7951 2000 Fax: + 44 20 7951 1345 ey.com Directorate-General for Taxation and Customs Union European Commission Rue de Spa 3, Office 5/82
More informationRegulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.
Regulatory Support for Tobacco Products Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help. PREMARKET TOBACCO (PMTA) HUMAN FACTORS STUDIES SUBSTANTIAL EQUIVALENCE
More informationFDA Center for Tobacco Products: Tobacco Research and the Population Assessment of Tobacco and Health (PATH) Study
FDA Center for Tobacco Products: Tobacco Research and the Population Assessment of Tobacco and Health (PATH) Study Regulatory Public Laws Compliance & Education Policies Science & Enforcement & Communications
More informationCancer and its Causes in Korea
Cancer and its Causes in Korea Prof. Dr. David Khayat, MD, PhD Former Head of Medical Oncology at Pitié-Salpêtrière in Paris Former President of the National Cancer Institute in France Harm Reduction Consultant
More informationTobacco Control Research and Education, University of California San Francisco, San Francisco, CA, USA
The Difference between IQOS and Continued Smoking Response to the article entitled PMI s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different
More informationHow to Regulate E-Cigarettes? Are we asking the right questions?
How to Regulate E-Cigarettes? Are we asking the right questions? Eric N. Lindblom Director, Tobacco Control and Food & Drug Law O Neill Institute for National & Global Health Law Georgetown University
More informationStudy Summary Study THS-PBA-02-US
Page 1 Study Summary Study THS-PBA-02-US Study Title: Sponsor: Qualitative Study to Develop THS 2.2 Hypothetical Product Messages Philip Morris International Management S.A. Avenue de Rhodanie, 50 1007
More information